You are here
- Home
- Therapy Areas
- Respiratory/Inflammation
A naturalistic, prospective, single-center, double-blinded, fixed-dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200mg per day versus 400mg per day quetiapine fumarate in 200 drug-naïve first-episode psychosis patients aged 15-25 years.
- Disease
- asthma
- Drug Name
- Pulmicort
- Generic Name
- budesonide
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Jul 1, 1999
- Study Name
- AD-004-0001
- Study Id
- AD-004-0001
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
